IPP Bureau
Novo Nordisk & Vivtex team up to revolutionize oral hiologics
By IPP Bureau - February 27, 2026
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Merck Animal Health gets FDA nod for groundbreaking dog allergy drug NUMELVI
By IPP Bureau - February 27, 2026
Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds
By IPP Bureau - February 26, 2026
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Zydus to disrupt GLP-1 market with day-1 launch of innovative Semaglutide in India
By IPP Bureau - February 26, 2026
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy
By IPP Bureau - February 26, 2026
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
Alembic Pharma secures USFDA approval for generic Lamotrigine orally disintegrating tablets
By IPP Bureau - February 26, 2026
The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder
Eugia Pharma receives USFDA Approval for Everolimus tablets
By IPP Bureau - February 26, 2026
Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth
By IPP Bureau - February 26, 2026
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
Volta Labs unveils push-button PCR-free whole genome sequencing kit
By IPP Bureau - February 26, 2026
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Envoy Medical secures three new patents, bolstering cochlear implant leadership
By IPP Bureau - February 26, 2026
The new patents cover critical advancements in cochlear implant technology
Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
By IPP Bureau - February 26, 2026
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million
By IPP Bureau - February 26, 2026
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Alembic announces USFDA final approval for Efinaconazole Topical Solution, 10%
By IPP Bureau - February 25, 2026
Efinaconazole Topical Solution is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.
Caplin Steriles gets USFDA approval for Sodium Phosphate injection
By IPP Bureau - February 25, 2026
Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake
Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
By IPP Bureau - February 25, 2026
Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older
